Novo Nordisk A/S (NVO) Projected to Announce Earnings on Wednesday

Novo Nordisk A/S (NYSE:NVO) is expected to be issuing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $0.7310 per share and revenue of $11.07 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 7:00 AM ET.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The company had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. On average, analysts expect Novo Nordisk A/S to post $3.42 EPS for the current fiscal year and $3.42 EPS for the next fiscal year.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $40.43 on Tuesday. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55. The firm has a market cap of $180.52 billion, a price-to-earnings ratio of 9.89, a PEG ratio of 1.30 and a beta of 0.76. The stock has a 50 day moving average of $41.10 and a 200-day moving average of $44.24.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were paid a dividend of $0.5786 per share. This represents a yield of 258.0%. This is a drop from Novo Nordisk A/S’s previous dividend of $1.2751. The ex-dividend date was Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 19.80%.

Analyst Ratings Changes

A number of research firms have commented on NVO. Cfra downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 price objective for the company. in a report on Tuesday, September 22nd. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Novo Nordisk A/S in a research note on Tuesday, September 29th. Weiss Ratings cut shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. DZ Bank restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Friday, October 9th. Five investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus price target of $59.44.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.